CSP
1 min read
13

AEROF Sweden Bondco AB (publ) announces sale of La Tour, Aarhus

January 11, 2025
0

Reading Time: < 1 minute AEROF Sweden Bondco AB (publ) (the “Company“) announces the signing of a share purchase agreement in respect of the sale of the property known as La Tour, Aarhus, Denmark. The total sale price is based on a property value of

Continue Reading
CSP
9 min read
35

Symrise’s recommended offer to the shareholders of Probi expires soon; regulatory approval received

January 10, 2025
0

Reading Time: 6 minutes The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares be accepted from or on behalf of shareholders in, any jurisdiction in which the making of

Continue Reading
CSP
1 min read
34

#25-8 Listing of Derivatives at NGM

January 10, 2025
0

Reading Time: < 1 minute Information about various derivatives that will be listed at NGM. For more details, see attached file. For further information concerning this NGM notice please contact NGM Listing department on listings@ngm.se. Nordic Growth Market NGM AB About NGM Nordic Growth Market

Continue Reading
CSP
1 min read
35

ALEXANDRIA GROUP OYJ: ACQUISITION OF OWN SHARES 10.01.2025

January 10, 2025
0

Reading Time: < 1 minute   ALEXANDRIA GROUP OYJ NOTIFICATION     10.01.2025 at 18:30 EET   ALEXANDRIA GROUP OYJ: ACQUISITION OF OWN SHARES 10.01.2025   Date 10.01.2025   Exchange transaction Buy   Share class ALEX   Amount 10   Average price/share 8,7500 EUR Highest

Continue Reading
Fitch Affirms Investment Grade Rating of ’BBB-’ for Heimstaden Bostad, Raised Outlook to Stable
CSP
1 min read
35

Fitch Affirms Investment Grade Rating of ’BBB-’ for Heimstaden Bostad, Raised Outlook to Stable

January 10, 2025
0

Reading Time: < 1 minute Fitch affirms Heimstaden Bostad’s Long-Term Issuer Default rating (IDR) of ‘BBB-‘ and raises the Outlook to Stable from Negative. Co-CEO Christian Fladeland comments:  “The stable outlook validates that Heimstaden Bostad continues to deliver on its base case performance which

Continue Reading
CSP
3 min read
15

Sobi’s full year 2024 revenue higher than previous estimate

January 10, 2025
0

Reading Time: 2 minutes Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) announces today that revenue for the full year 2024 was higher than previous estimate. Full-year revenue was approximately SEK 26,000 M, representing approximately 19% growth at constant exchange rate (CER) (1). Adjusted EBITA margin (1,2)

Continue Reading
CSP
1 min read
16

ABAX disputes Greater Than’s claims in its entirety

January 10, 2025
0

Reading Time: < 1 minute Read original Larvik (Norway), January 10, 2025 – In reference to the press release of January 10th issued by Greater Than, accusing ABAX of infringing upon contractually regulated intellectual property (IP) rights, ABAX categorically refutes these allegations. ABAX find it

Continue Reading
CSP
5 min read
19

STENOCARE A/S announces guarantee commitments in ongoing rights issue

January 10, 2025
0

Reading Time: 3 minutes STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENO STENOCARE A/S (“Stenocare” or the “Company”) announces that the Company has received a legally binding guarantee commitment of 2 mDKK from Exelity AB, securing approximately 9.9 percent of the total issue corresponding to approximately

Continue Reading
CSP
1 min read
17

Invitation to monthly digital events and presentations of quarterly report

January 10, 2025
0

Reading Time: < 1 minute Hamlet BioPharma is pleased to announce the continuation of the digital event series in the spring of 2025. These events provide participants a valuable opportunity to follow and discuss our drug development process and engage directly with our team during

Continue Reading
CSP
2 min read
16

UNION therapeutics to present at the Dermatology Summit 2025, opening the week of the 43rd Annual J.P. Morgan Health Care Conference

January 10, 2025
0

Reading Time: 2 minutes Hellerup, Denmark, January 10, 2025 – UNION therapeutics A/S (UNION), a privately held, clinical stage, pharmaceutical development company focused on immunology, today announced that CEO Dr. Kim Kjøller will present at the Dermatology Summit, January 12th 2025 at the Hyatt Regency

Continue Reading